Clinical Trial Update: Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for abiraterone acetate in metastatic hormone-resistant prostate cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)

Snippet

Sponsor: University of Washington | Conditions: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-05-14